GLP-1 medications act on receptors in the brain and gut to increase feelings of fullness, decrease cravings, slow stomach emptying, and improve blood sugar regulation
In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients
The three FDA-approved injection sites for subcutaneous GLP-1 administration are the abdomen, the front or outer thigh, and the back of the upper arm
However, adequate adjustment of insulin doses and close monitoring after GLP-1RA initiation may decrease this risk
Community reports describe the days 4-7 window as the period of greatest blood-sugar awareness, with several users describing the need for fast carbs on hand